Perbedaan Ekspresi Reseptor Hormonal Antara Pasien Premenopausal dan Postmenopausal Pada Kanker Payudara Di RSUP H. Adam Malik Medan
40
DAFTAR PUSTAKA
Ahmed HG, Al-Adhraei MA, Al-Thobhani AK.(2011) Correlation of Hormone
Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal
Carcinoma Among Yemeni Women. The Open Cancer Immunology
Jounal. 4,1-9
American Cancer Society, (2013). Breast Cancer Fact & Figures 2013-2014.
Asako O, Takaharab S, Sumiyoshia K, Yamamotoa H, Kawaic J andShibaa E
(2013) Relationship between intrinsic subtypes and tumor responses to
neoadjuvant chemotherapy in patients with locally advanced breast
cancer.Breast Disease 34 (2012/2013) 9-17
Azim Jr HA, Partridge AH, (2014) Review :Biology of Breast Cancer in Young
Women. Breast Cancer Research 16:427:p1-9
Baziad A. (2008). Endokrinologi Ginekologi edisi ketiga: Menopause.Penerbit
Media Aesculapius Fakultas Kedokteran Universitas Indonesia. Hal.115117.
Berstadt, P, Coates R J, Bernsteins L, Folger S G, Malone K E, Marchbanks P A,
et al (2010). A Case Control Studyof Body Mass Index and Breast Cancer
Risk in White and African- American Women. Cancer Epidemiologic
Biomarkes, 1532-1544.
Brufsky AM, (2011).Understanding the estrogen receptor signaling pathway focus
on current endocrine agents for breast cancer in postmenopausal women
(review). Community Oncology;8:343-52.
Byrd DR, Edge SB (2010) AJCC Breast Cancer Staging Manual, 7th Ed. New
York. NY: Springer.p347-76
Dahlan MS, (2013) Besar Sampel dan Cara Pengambilan Sampel edisi 3, Penerbit
Salemba Medika
Departemen Kesehatan Republik Indonesia, (2013) Pemerintah Targetkan 80%
Perempuan dapat Deteksi Dini Kanker Payudara dan Kanker Serviks.
Direktorat Jenderal PP & PL Kementerian Kesehatan, 2013. Panduan
Memperingati Hari kanker sedunia di Indonesia Tahun 2013.
41
Devita VT, Hellman S, Rosenberg SA.(2008) Penyunting. Cancer Principles and
practice of oncology. Edisi ke-8. Philadelphia. Lippincott william &
Wilkins.
Dillon D, Guidi AJ, Schnitt SJ. (2014) Pathology of Invasive Breast Cancer. In
Disease of the Breast. 5th ed. Haris JR, Lippoman ME, Morrow M,
Osborne CK( editors). Wolters Klumer Health. p381-410
Dowsett M, Miller W. (2014) Estrogen and Progesterone Receptor Testing for
Prognosis and Prediction. In Disease of the Breast. 5th ed. Haris JR,
Lippoman ME, Morrow M, Osborne CK( editors). Wolters Klumer
Health.p411-22
Dunwald LK, Rossing MA, Li CI. (2007) Breast Cancer Researh. Hormon
receptor status, tumor characteristics, and prognosis: a prospective cohort
of breast cancer patients.
Ellis IO, Schinitt SJ, Satre GX, (2003) Invasive Breast Carcinoma in World
Health Organization Classification of Tumours Pathology & Genetics
Tumours of Breast and Female Genital Organs. IARC; 13-59
Fabian CJ, Kivoler BF (2005). Selective Estrogen Receptor Modulator for
Primary Prevention of Breat Cancer. J. Clinical Oncology.p.1644-55
Globocan, (2012) Breast Cancer Incidence and Mortality Worldwide in 2012
Summary.
Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K. (2014) Higher
Incidence of Premenopausal Breast Cancer in Less DevelopedCountries ;
Myth or Ruth? BMC Cancer 14: 343;p1-8
Hammond MEH, Daniel F, Hayes, Dowsett M, Allerd DC, Karen L et al (2010)
American Society of Clinical Oncology/College of American Pathologists
Guideline Recommendations for Immunohistochemical Testing of
Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical
Oncology. Volume 28 16:2784-2792
Haroon, Saroona., Hashmi, Atif Ali., Khurshid, Amna., Kanpurwala, Muhammad
Adnan., Mutjuba, Shafaq., Malik, Babar., et al, (2013) Ki-67 Index in
Breast Cancer: Correlation with Other Prognostic Markers and Potential in
42
Pakistani Patients. Asian Pacific Journal of Cancer Prevention 14: 43534357
Huang,W.,Newman, B., Millikan, R., Schell, M., Hulka,B., & Moorman,P.(2000)
Hormone-related Factors and Risk of Breast Cancer in Relation to
Estrogen Receptor and Progesterone Receptor Status. American Journal of
Epidemiology, 703-714.
Kardinal CG.( 2002) Hormonal and Endocrine Therapy of Breast Cancer. In
Cancer of the Breast. 5th Ed. Donegan WL, Spratt JS (Editors).
Saunders.p693-726
Kartika EPI,Maulani H, Sulastri H, Yuwono.(2009) Ekspresi Protein Her-2/net,
Status Reseptor Estrogen dan Progesteron pada berbagai Derajat
Keganasan Karsinoma Payudara Duktal Invasif Wanita Usia Muda.
Majalah Patologi Vol. 18 No.1:p32-41
Kuiper GG, Enmark E, Pelto-Huiko M, Nilsson S, Gustafsson JA. (1996) Cloning
of a Novel Receptor Expressed in Rat Prostate and Ovary. Proc.Nattl.
Acad. Sci. USA, 93(12):p5925-30
Lari SA and Kuerer HM, (2011) Review: Biological Markers in DCIS and Risk of
Breast Recurrence: A Systemetic Review. Journal of Cancer 2; 232-61
Levin ER,(2005), Integration of Extranuclear and Nuclear Actions of Estrogen.
Mol. Endrocrinologi. 19(8):p1951-9
Payne SJL, Bowen RL, Jones JL & Wells CA. (2008) Predictive markers in breast
cancer- the present histopatholgy;52: 82-90
Petricevic J, Petkovic M, Jonjic N. (2011) Expression of Estrogen and
Progesterone Receptors in Human Ductal Invasive Breast Carcinoma Not
Otherwise Specified : Is there any Difference Between Premenoausal and
Postmenopausal Women?. Acta Clin Croat; 50: 169-175
Rajan G, Culas TC, Jayalakshmy PS.(2014) Estrogen and Progesterone Receptor
Status of 450 Women in Kerala, South India. World Journal of surgical
Oncology.12:120 p1-4
Ramli, Muchlis, (1995) Kanker Payudara. Dalam: Kumpulan Kuliah Ilmu Bedah.
Jakarta: Binarupa Aksara, 342-364.
43
Rosai J. (2004). Breast. In Rosai and Aekerman’s Surgical Pathology, 9th Ed.
Philadelphia: Elsevier,p.1763-1877
Rumah Sakit Umum Pendidikan H.Adam Malik Medan, (2012) Data Kasus
Keganasan Payudara 2008-2011. [Unpublished].
Shanaz N. Profil Hormonal Reseptor pada Pemeriksaan Immunohistokimia pada
Pasien Kanker Payudara di RSUD dr. Soetomo pada tahun 2009.Fakultas
Kedokteran Universitas Airlangga. Surabaya 2010
Suyatno, Pasaribu ET, (2014) Bedah Onkologi; Diagnosis dan terapi, edisi ke-2.
Seagung Seto. Jakarta.
Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. (2002)
Hormone Receptors and Proliferation in Breast Carcinomas of Equivalent
Histologic in Pre- and Postmenopausal Women. Int. J. Cancer: 98, p118127
Vasei M, Azarpira N, Talei A.(2006) Status of Estrogen and Progesterone
Receptors in Various Phases of the Menstrual Cycle in Breast Cancer.
Archive of Iranian Medicine, volume 9(3):250-253
Viale G, Regan MM, Mastropasqua MG, Maiorano E, Colleoni M, Price KN et al
(2008). Predictive value of tumor Ki-67 expression in two randomized
trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
J Natl Cancer Inst. 100:207-212
Yanger
JD,
Davidson
NE.(2006).
Mechanisms
of
disease,
Carcinogenesis in Breast Cancer. New England Journal of
Estrogen
Medicine;
354:270-82
Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al
(2012). Luminal A and luminal B (HER2 negative) subtypes of breast
cancer consist of a mixture of tumor with different genotype. BMC
Reasearch Notes 5:376;p1-8
Weigel MT and Dowsett M, (2010) Review; Current and emerging biomarkers in
breast cancer: prognosis and prediction; Endocrine- Related Cancer
.17:R245-R262
WHO, 2013. Breast Cancer: Prevention and Control.
44
Zhang MH, Man HT, Zhao, Dong N and Ma SL, (2013) Estrogen receptorpositive breast cancer molecular signatures and therapeutic potentials
(Review).Biomedical Reports; 2:41-52
DAFTAR PUSTAKA
Ahmed HG, Al-Adhraei MA, Al-Thobhani AK.(2011) Correlation of Hormone
Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal
Carcinoma Among Yemeni Women. The Open Cancer Immunology
Jounal. 4,1-9
American Cancer Society, (2013). Breast Cancer Fact & Figures 2013-2014.
Asako O, Takaharab S, Sumiyoshia K, Yamamotoa H, Kawaic J andShibaa E
(2013) Relationship between intrinsic subtypes and tumor responses to
neoadjuvant chemotherapy in patients with locally advanced breast
cancer.Breast Disease 34 (2012/2013) 9-17
Azim Jr HA, Partridge AH, (2014) Review :Biology of Breast Cancer in Young
Women. Breast Cancer Research 16:427:p1-9
Baziad A. (2008). Endokrinologi Ginekologi edisi ketiga: Menopause.Penerbit
Media Aesculapius Fakultas Kedokteran Universitas Indonesia. Hal.115117.
Berstadt, P, Coates R J, Bernsteins L, Folger S G, Malone K E, Marchbanks P A,
et al (2010). A Case Control Studyof Body Mass Index and Breast Cancer
Risk in White and African- American Women. Cancer Epidemiologic
Biomarkes, 1532-1544.
Brufsky AM, (2011).Understanding the estrogen receptor signaling pathway focus
on current endocrine agents for breast cancer in postmenopausal women
(review). Community Oncology;8:343-52.
Byrd DR, Edge SB (2010) AJCC Breast Cancer Staging Manual, 7th Ed. New
York. NY: Springer.p347-76
Dahlan MS, (2013) Besar Sampel dan Cara Pengambilan Sampel edisi 3, Penerbit
Salemba Medika
Departemen Kesehatan Republik Indonesia, (2013) Pemerintah Targetkan 80%
Perempuan dapat Deteksi Dini Kanker Payudara dan Kanker Serviks.
Direktorat Jenderal PP & PL Kementerian Kesehatan, 2013. Panduan
Memperingati Hari kanker sedunia di Indonesia Tahun 2013.
41
Devita VT, Hellman S, Rosenberg SA.(2008) Penyunting. Cancer Principles and
practice of oncology. Edisi ke-8. Philadelphia. Lippincott william &
Wilkins.
Dillon D, Guidi AJ, Schnitt SJ. (2014) Pathology of Invasive Breast Cancer. In
Disease of the Breast. 5th ed. Haris JR, Lippoman ME, Morrow M,
Osborne CK( editors). Wolters Klumer Health. p381-410
Dowsett M, Miller W. (2014) Estrogen and Progesterone Receptor Testing for
Prognosis and Prediction. In Disease of the Breast. 5th ed. Haris JR,
Lippoman ME, Morrow M, Osborne CK( editors). Wolters Klumer
Health.p411-22
Dunwald LK, Rossing MA, Li CI. (2007) Breast Cancer Researh. Hormon
receptor status, tumor characteristics, and prognosis: a prospective cohort
of breast cancer patients.
Ellis IO, Schinitt SJ, Satre GX, (2003) Invasive Breast Carcinoma in World
Health Organization Classification of Tumours Pathology & Genetics
Tumours of Breast and Female Genital Organs. IARC; 13-59
Fabian CJ, Kivoler BF (2005). Selective Estrogen Receptor Modulator for
Primary Prevention of Breat Cancer. J. Clinical Oncology.p.1644-55
Globocan, (2012) Breast Cancer Incidence and Mortality Worldwide in 2012
Summary.
Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K. (2014) Higher
Incidence of Premenopausal Breast Cancer in Less DevelopedCountries ;
Myth or Ruth? BMC Cancer 14: 343;p1-8
Hammond MEH, Daniel F, Hayes, Dowsett M, Allerd DC, Karen L et al (2010)
American Society of Clinical Oncology/College of American Pathologists
Guideline Recommendations for Immunohistochemical Testing of
Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical
Oncology. Volume 28 16:2784-2792
Haroon, Saroona., Hashmi, Atif Ali., Khurshid, Amna., Kanpurwala, Muhammad
Adnan., Mutjuba, Shafaq., Malik, Babar., et al, (2013) Ki-67 Index in
Breast Cancer: Correlation with Other Prognostic Markers and Potential in
42
Pakistani Patients. Asian Pacific Journal of Cancer Prevention 14: 43534357
Huang,W.,Newman, B., Millikan, R., Schell, M., Hulka,B., & Moorman,P.(2000)
Hormone-related Factors and Risk of Breast Cancer in Relation to
Estrogen Receptor and Progesterone Receptor Status. American Journal of
Epidemiology, 703-714.
Kardinal CG.( 2002) Hormonal and Endocrine Therapy of Breast Cancer. In
Cancer of the Breast. 5th Ed. Donegan WL, Spratt JS (Editors).
Saunders.p693-726
Kartika EPI,Maulani H, Sulastri H, Yuwono.(2009) Ekspresi Protein Her-2/net,
Status Reseptor Estrogen dan Progesteron pada berbagai Derajat
Keganasan Karsinoma Payudara Duktal Invasif Wanita Usia Muda.
Majalah Patologi Vol. 18 No.1:p32-41
Kuiper GG, Enmark E, Pelto-Huiko M, Nilsson S, Gustafsson JA. (1996) Cloning
of a Novel Receptor Expressed in Rat Prostate and Ovary. Proc.Nattl.
Acad. Sci. USA, 93(12):p5925-30
Lari SA and Kuerer HM, (2011) Review: Biological Markers in DCIS and Risk of
Breast Recurrence: A Systemetic Review. Journal of Cancer 2; 232-61
Levin ER,(2005), Integration of Extranuclear and Nuclear Actions of Estrogen.
Mol. Endrocrinologi. 19(8):p1951-9
Payne SJL, Bowen RL, Jones JL & Wells CA. (2008) Predictive markers in breast
cancer- the present histopatholgy;52: 82-90
Petricevic J, Petkovic M, Jonjic N. (2011) Expression of Estrogen and
Progesterone Receptors in Human Ductal Invasive Breast Carcinoma Not
Otherwise Specified : Is there any Difference Between Premenoausal and
Postmenopausal Women?. Acta Clin Croat; 50: 169-175
Rajan G, Culas TC, Jayalakshmy PS.(2014) Estrogen and Progesterone Receptor
Status of 450 Women in Kerala, South India. World Journal of surgical
Oncology.12:120 p1-4
Ramli, Muchlis, (1995) Kanker Payudara. Dalam: Kumpulan Kuliah Ilmu Bedah.
Jakarta: Binarupa Aksara, 342-364.
43
Rosai J. (2004). Breast. In Rosai and Aekerman’s Surgical Pathology, 9th Ed.
Philadelphia: Elsevier,p.1763-1877
Rumah Sakit Umum Pendidikan H.Adam Malik Medan, (2012) Data Kasus
Keganasan Payudara 2008-2011. [Unpublished].
Shanaz N. Profil Hormonal Reseptor pada Pemeriksaan Immunohistokimia pada
Pasien Kanker Payudara di RSUD dr. Soetomo pada tahun 2009.Fakultas
Kedokteran Universitas Airlangga. Surabaya 2010
Suyatno, Pasaribu ET, (2014) Bedah Onkologi; Diagnosis dan terapi, edisi ke-2.
Seagung Seto. Jakarta.
Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. (2002)
Hormone Receptors and Proliferation in Breast Carcinomas of Equivalent
Histologic in Pre- and Postmenopausal Women. Int. J. Cancer: 98, p118127
Vasei M, Azarpira N, Talei A.(2006) Status of Estrogen and Progesterone
Receptors in Various Phases of the Menstrual Cycle in Breast Cancer.
Archive of Iranian Medicine, volume 9(3):250-253
Viale G, Regan MM, Mastropasqua MG, Maiorano E, Colleoni M, Price KN et al
(2008). Predictive value of tumor Ki-67 expression in two randomized
trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
J Natl Cancer Inst. 100:207-212
Yanger
JD,
Davidson
NE.(2006).
Mechanisms
of
disease,
Carcinogenesis in Breast Cancer. New England Journal of
Estrogen
Medicine;
354:270-82
Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al
(2012). Luminal A and luminal B (HER2 negative) subtypes of breast
cancer consist of a mixture of tumor with different genotype. BMC
Reasearch Notes 5:376;p1-8
Weigel MT and Dowsett M, (2010) Review; Current and emerging biomarkers in
breast cancer: prognosis and prediction; Endocrine- Related Cancer
.17:R245-R262
WHO, 2013. Breast Cancer: Prevention and Control.
44
Zhang MH, Man HT, Zhao, Dong N and Ma SL, (2013) Estrogen receptorpositive breast cancer molecular signatures and therapeutic potentials
(Review).Biomedical Reports; 2:41-52